Metastatic Prostate Cancer Survivor – Buddy's Envita Review
Buddy was diagnosed with metastatic prostate cancer in the fall of 2019; he was given a maximum of 36 months to live. His former doctors told him there was little they could do, and he should cherish the time he had left with his family. After talking with his wife, Buddy decided to pursue alternative treatment opportunities and found Envita Medical Centers to be his “best option”.
Buddy was drawn to Envita because of the personalized treatment options we offer. Our unique, customized integrative approach has helped thousands of complex end-stage and nonresponsive-to-care cancer patients find amazing results with advanced treatment options that go beyond standardized cancer care models. Buddy's genetically based, patient-specific cancer treatment protocol, delivered in a caring environment at Envita, left him “extremely pleased” with the progress he has made under Envita's care.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
Like many of the patients that arrive at Envita, Buddy was diagnosed with late-stage progressive cancer and given few options for treatment by standard medicine. By treating Buddy, and all our patients, as unique individual cases of cancer, we can better target therapy to give our patients the best chances for progression against their cancer. Envita's next-level genomic diagnostics and precision-targeted cancer treatments help our patients achieve a greater opportunity for success. In Buddy's words. “I did not feel like I was one of many. I felt like I was one of one”.
Envita uses genetic testing to properly identify every patient's unique form of cancer and then build a comprehensive protocol composed of genetically targeted chemotherapies, customized adjunctive infusions, and immunotherapies. By targeting chemotherapy based on the patient's individual cancer markers, Envita's Genetically Targeted Fractionated Chemotherapy (GTFC™) is designed to “minimize the negative impact of chemotherapy while maximizing the benefits.” This often results in decreased chemotherapy symptoms that are not only difficult for the patient to go through but can also deplete the patient's immune system and stunt recovery. Buddy, like many of our cancer patients, “had very few negative effects from” his GTFC™.
Buddy was very pleased with his experience at Envita, and he could tell that “these are very compassionate people, and they believe in what they are doing.” He could see that everyone who works at Envita was truly invested in helping him and were “genuinely nurturing and caring.” Buddy felt compassionate respect from his doctors and all the staff. He was impressed by Dr. Poteet's knowledge and how Dr. Poteet took the time to properly educate and inform Buddy throughout his healing journey. Buddy also “developed a great relationship with his charge nurse,” and he is grateful for the motivation she gave.
Buddy is one of the many late-stage cancer patients Envita has been able to help over the last two decades. Buddy feels that “Envita has a targeted personalized approach that gave me a very positive outcome.” If you or a loved one is suffering from any type of cancer, early or late-stage, please contact our patient care coordinators at 866-830-4576 and see what advanced personalized medicine can do to help you.
